- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03623061
F-Point Validation Study (F-Point)
A Clinical Study to Define Precision, Accuracy, and Comparability of Results From a Novel Point of Care Fibrinogen Assay (F-Point), Compared to an Industry Standard
Study Overview
Detailed Description
The area to be investigated is the measurement of blood fibrinogen concentration. The aim is to develop a device which can give a fibrinogen level rapidly and accurately, in order to allow decision making quickly in emergency haemorrhage situations.
Postpartum hemorrhage (PPH) is one of the leading causes of maternal mortality and morbidity throughout the world and is accountable for 27.1% of maternal deaths worldwide according to a recent WHO systematic analysis.1 The confidential enquiry into maternal deaths and morbidity 2012 - 2014 describes 13 deaths from maternal haemorrhage.2 Fibrinogen is an component of the coagulation cascade. It is the principal factor for the final stage of clot formation. The fibrinogen level increases during pregnancy from the first through to third trimester.3 During a PPH this level decreases rapidly, influenced by two principal mechanisms, the loss of the blood itself and the consumption of coagulation factors associated with coagulation activation. Fibrinogen level below 2g/L in the early phase of PPH correlates with subsequent development of severe PPH.4 The conventional laboratory tests (Clauss, PT-derived) are time consuming, and workload intensive for laboratory staff. This has implications in terms of decision making in a rapidly changing clinical environment during a massive PPH. A point of care test, with more rapidly available results at the patient location should improve the speed of decision making based on individual patient data. The focus of this study is to validate the fibrinogen concentration as measured by the F-point device compared to the laboratory standard Clauss fibrinogen. The F-Point is second generation POC device that is compatible with deployment within the emergency room or operating theater. By having rapid access to fibrinogen concentration results, early and individualized treatment can be implemented with the aim of improving patient outcomes, with a possible decrease in unnecessary administration of fibrinogen.
We aim to show equivalent performance between the F-Point device in 3 populations.
- Healthy non-pregnant females presenting for elective gynaecology surgery
- Healthy pregnant females presenting for elective caesarean section
- Anonymised low fibrinogen adult samples from the laboratory
These 3 populations have been chosen to demonstrate device performance in:
- Normal non-pregnant fibrinogen concentrations
- Normal term pregnancy fibrinogen levels
- Low fibrinogen concentrations By demonstrating equivalent and acceptable performance at these 3 fibrinogen concentration ranges, we would expect to show performance of the device to be acceptable for clinical use across the spectrum of patients presenting to maternity hospitals.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Luke Heaphy, BSc
- Phone Number: 2540 01 817 2540
- Email: lukeheaphy@rcsi.com
Study Locations
-
-
-
Dublin 1, Ireland
- Recruiting
- Obstetrics & Gynaecology, The Rotunda Hospital
-
Contact:
- Luke Heaphy, BSc
- Phone Number: 01 817 2540
- Email: lukeheaphy@rcsi.com
-
Principal Investigator:
- Patrick Thornton
-
Sub-Investigator:
- Richard Katz
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Group 1: Elective Caesarean section Group 2: Elective gynaecological procedure
•Group 3 will consist of anonymous patient samples
Description
Inclusion Criteria:
- Participant is willing and able to give informed consent for participation in the clinical investigation.
- Female, aged 18 years or above.
- Able (in the Investigators opinion) and willing to comply with all clinical investigation requirements.
- Presenting for Group 1: Elective Caesarean section Group 2: Elective gynaecological procedure
- Group 3 will consist of anonymous patient samples
Exclusion Criteria:
Patients on any antiplatelet or anticoagulant medications
o Patients prescribed subcutaneous low molecular weight heparin medications are permitted to enrol, provided the timing of sampling is outside of 24 hours after the last dose of the medication.
- Any patient with a known thrombophilia or a known haemophilia.
- Any patient with a known dysfibrinogenaemia except in the anonymous low fibrinogen group
- Patients with a known malignancy or autoimmune condition affecting blood clotting
- A personal history of easy bruising strongly suggestive of a blood clotting disorder
- Any reason, in the opinion of the investigator that would make the subject unsuitable for participation
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Low Fibrinogen Level
Anonymised low fibrinogen adult samples from the laboratory (Low fibrinogen concentrations).
Samples to be tested on the F-Point device and standard Clauss Fibrinogen assay.
|
F-Point (point of care in vitro diagnostic device for measuring plasma fibrinogen concentration)
|
Normal Fibrinogen Level
Healthy non pregnant females presenting for elective gynaecology surgery (Normal non pregnant fibrinogen concentrations) Samples to be tested on the F-Point device and standard Clauss Fibrinogen assay.
|
F-Point (point of care in vitro diagnostic device for measuring plasma fibrinogen concentration)
|
High Fibrinogen Level
Healthy pregnant females presenting for elective caesarean section (Normal term pregnancy fibrinogen levels) Samples to be tested on the F-Point device and standard Clauss Fibrinogen assay.
|
F-Point (point of care in vitro diagnostic device for measuring plasma fibrinogen concentration)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Measurement of Fibrinogen concentration
Time Frame: Within 2 hours of blood drawn
|
To demonstrate equivalent performance between a novel point of care device, the F-point, when compared to the laboratory Clauss assay for measuring fibrinogen concentration.
|
Within 2 hours of blood drawn
|
Collaborators and Investigators
Investigators
- Principal Investigator: Patrick Thornton, Rotunda Hospital
Publications and helpful links
General Publications
- Say L, Chou D, Gemmill A, Tuncalp O, Moller AB, Daniels J, Gulmezoglu AM, Temmerman M, Alkema L. Global causes of maternal death: a WHO systematic analysis. Lancet Glob Health. 2014 Jun;2(6):e323-33. doi: 10.1016/S2214-109X(14)70227-X. Epub 2014 May 5.
- Gong JM, Shen Y, He YX. Reference Intervals of Routine Coagulation Assays During the Pregnancy and Puerperium Period. J Clin Lab Anal. 2016 Nov;30(6):912-917. doi: 10.1002/jcla.21956. Epub 2016 Apr 7.
- Charbit B, Mandelbrot L, Samain E, Baron G, Haddaoui B, Keita H, Sibony O, Mahieu-Caputo D, Hurtaud-Roux MF, Huisse MG, Denninger MH, de Prost D; PPH Study Group. The decrease of fibrinogen is an early predictor of the severity of postpartum hemorrhage. J Thromb Haemost. 2007 Feb;5(2):266-73. doi: 10.1111/j.1538-7836.2007.02297.x. Epub 2006 Nov 6.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- FPoint-V1-0418
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Low Fibrinogen
-
Société Française d'Anesthésie et de RéanimationKeyrus BiopharmaUnknownCardiac Surgery | Extracorporeal Circulation | Fibrinogen
-
Hospital Clinic of BarcelonaUniversity of BarcelonaCompletedFibrinogen; Deficiency, Acquired | PHARMACOKINETICSSpain
-
University Health Network, TorontoCompleted
-
OctapharmaCompletedCongenital Fibrinogen DeficiencyIndia, Iran, Islamic Republic of, Lebanon
-
OctapharmaCompletedCongenital Fibrinogen DeficiencyUnited States, Bulgaria, India, Iran, Islamic Republic of, Lebanon, Russian Federation, Saudi Arabia, Turkey, United Kingdom
-
CSL BehringCompletedCongenital Fibrinogen DeficiencyUnited States, Canada
-
IsalaCSL BehringCompletedFibrinogen Deficiency in Complex Cardiac SurgeryNetherlands
-
OctapharmaRecruitingCongenital Fibrinogen DeficiencyGermany
-
OctapharmaCompletedCongenital Fibrinogen Deficiency | AfibrinogenemiaIran, Islamic Republic of, United States, Bulgaria, India, Switzerland, United Kingdom
Clinical Trials on F-Point
-
University of SaskatchewanSaskatoon Health Region; Sylvia Fedoruk Canadian Centre for Nuclear InnovationCompletedPositron-Emission Tomography and Cone-Beam Computed Tomography
-
University Hospital, CaenRecruitingDeep Vein ThrombosisFrance
-
Johns Hopkins UniversityTerminatedChemotherapy-induced Peripheral Neuropathy (CIPN)United States
-
Leipzig Heart Institute GmbHSuspended
-
Children's Hospital Medical Center, CincinnatiRecruitingLow Back Pain | Chronic Widespread Pain | Fibromyalgia | Complex Regional Pain Syndrome (CRPS) | Ehlers-Danlos Syndrome (EDS) | Amplified Musculoskeletal Pain Syndrome (AMPS)United States
-
Centre Hospitalier Sud FrancilienCompleted
-
Point DesignsUniversity of Colorado, DenverCompletedAmputation; Traumatic, HandUnited States
-
Point DesignsUniversity of Colorado, Denver; Arm DynamicsCompletedAmputation; Traumatic, HandUnited States
-
Point DesignsUniversity of Colorado, Denver; Arm DynamicsCompletedAmputation; Traumatic, HandUnited States
-
Point DesignsUniversity of Colorado, DenverCompletedAmputation; Traumatic, HandUnited States